SCHEMBL3565261

SCHEMBL3565261

Cc1ccc([N+](=O)[O-])cc1Nc1ncccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
MCL1 Q07820 1/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GAA P10253 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TNF P01375 1/20 0.45
NOD1 Q9Y239 1/20 0.45
NFKBIA P25963 1/20 0.45
RELA Q04206 1/20 0.45
RORC P51449 1/20 0.44
MAPT P10636 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
P2RX7 Q99572 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28221126 0.81 ALDH1A1 (0.68) ALDH1A1HTTSMN1; SMN2GAAMEN1
SCHEMBL18388841 0.78 ABCG2 (0.52) ALDH1A1HTTSMN1; SMN2NPC1RAB9A
SCHEMBL3565258 0.78 ALDH1A1 (0.53) ALDH1A1MCL1HTTSMN1; SMN2GAA
SCHEMBL10586422 0.77 FGFR4 (0.56) ALDH1A1MCL1HTTSMN1; SMN2NPC1
SCHEMBL10106205 0.75 ALDH1A1 (0.50) ALDH1A1MCL1HTTSMN1; SMN2NPC1
SCHEMBL31671095 0.74 ALDH1A1 (0.62) ALDH1A1MCL1HTTSMN1; SMN2GAA
SCHEMBL3218848 0.74 ALDH1A1 (0.62) ALDH1A1MCL1HTTSMN1; SMN2GAA
SCHEMBL3569040 0.74 ALDH1A1 (0.55) ALDH1A1MCL1HTTSMN1; SMN2GAA
SCHEMBL10106211 0.73 ALDH1A1 (0.53) ALDH1A1HTTSMN1; SMN2NPC1GAA
SCHEMBL1241944 0.73 KMT2A (0.64) ALDH1A1MCL1HTTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299358-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2018-03-28 EP disclosed
EP-1702917-B1 AMIDE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2017-08-02 EP disclosed
US-7728131-B2 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia NIPPON SHINYAKU CO., LTD. (JP) 2010-06-01 US disclosed
EP-1533304-B1 AMIDE DERIVATIVE NIPPON SHINYAKU CO LTD (JP) 2009-11-04 EP disclosed
US-7494997-B2 Amide derivative NIPPON SHINYAKU CO., LTD. (JP) 2009-02-24 US disclosed
US-20080293940-A1 Amide Derivative and Medicine NIPPON SHINYAKU CO., LTD. (JP) 2008-11-27 US disclosed
EP-1702917-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2006-09-20 EP disclosed
US-20060014742-A1 Amide derivative NIPPON SHINYAKU CO., LTD. (JP) 2006-01-19 US disclosed
EP-1533304-A1 AMIDE DERIVATIVE Nippon Shinyaku Co., Ltd. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014742-A1 Amide derivative ABL1, ABL2, BCR ALDH1A1 753/4885MCL1 270/4885HTT 2559/4885
US-20080293940-A1 Amide Derivative and Medicine ABL2, ABL1, BCR ALDH1A1 518/4885MCL1 426/4885HTT 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.